Teleflex (TFX) Set to Post Quarterly Earnings on Thursday

Teleflex (NYSE:TFX) is anticipated to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Teleflex to announce earnings of $1.90 per share and revenue of $565.52 million for the quarter. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Teleflex (NYSE:TFX) last announced its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.28 by $0.48. The firm had revenue of $570.33 million for the quarter, compared to the consensus estimate of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.73 earnings per share. On average, analysts expect Teleflex to post $7.22 EPS for the current fiscal year and $10.89 EPS for the next fiscal year.

Teleflex Stock Up 0.6%

TFX stock opened at $140.54 on Tuesday. Teleflex has a one year low of $100.18 and a one year high of $145.00. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.12 and a current ratio of 2.60. The firm’s fifty day moving average is $131.39 and its 200 day moving average is $125.19. The firm has a market cap of $5.96 billion, a PE ratio of -6.03, a P/E/G ratio of 0.93 and a beta of 0.83.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TFX shares. UBS Group increased their target price on shares of Teleflex from $145.00 to $158.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 11th. Truist Financial cut their price target on Teleflex from $150.00 to $142.00 and set a “hold” rating for the company in a research note on Wednesday, October 14th. Mizuho upped their price target on Teleflex from $140.00 to $145.00 and gave the stock a “neutral” rating in a report on Wednesday, July 15th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Monday, September 21st. Finally, Needham & Company LLC increased their price target on Teleflex from $159.00 to $170.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $154.40.

Teleflex Company Profile

Teleflex Incorporated is a global medical technology company that develops, manufactures and markets specialty medical devices. Its products are designed to support healthcare professionals in critical care and procedural settings, including vascular access, interventional cardiology and radiology, anesthesia, respiratory care, emergency medicine, surgical applications and urology.

The company’s portfolio includes catheters, access and closure devices, airway-management products, surgical instruments, pain-management devices and other technologies used in hospitals and outpatient facilities.